PREGNOLIA AG

Their core work

Pregnolia AG is a Swiss medical device company developing diagnostic technology to assess the risk of preterm birth by measuring cervical stiffness. Their core product is a device designed for use in gynecological practices to identify high-risk pregnancies early, enabling timely clinical intervention. The company has progressed from initial feasibility through to clinical validation, following the classic SME Instrument pathway from Phase 1 to Phase 2 funding.

What they specialise in

How they've shifted over time

Pregnolia's H2020 trajectory shows a textbook SME Instrument progression rather than a thematic shift. Their 2018 Phase 1 project established feasibility for a preterm birth diagnostic device, followed in 2019 by the much larger Phase 2 project (EUR 1.28M) to develop and commercialize it. By 2020, the CervixCare project signals a move toward broader clinical validation and positioning the technology within standard prenatal care protocols.

Pregnolia is moving from R&D toward clinical deployment and market entry for their cervical stiffness diagnostic, suggesting they will next seek commercialization and regulatory partners.

How they like to work

Pregnolia operates exclusively as a solo coordinator — all three projects are SME Instrument grants with zero consortium partners. This is typical for early-stage medtech startups using EU funding to de-risk their own product development. Working with them would likely mean a supplier, clinical partner, or distribution relationship rather than a traditional consortium partnership.

Pregnolia has no recorded consortium partners in H2020, reflecting their use of single-beneficiary SME Instrument funding. Their collaboration network, if any, exists outside the CORDIS data — likely with clinical sites and university hospitals involved in device validation.

What sets them apart

Pregnolia occupies a very specific niche: non-invasive cervical stiffness measurement for preterm birth prediction — a problem affecting roughly 10% of pregnancies worldwide with limited existing diagnostic tools. Their progression through all SME Instrument stages with consistent EU backing signals strong technical credibility. For potential partners, they offer deep domain expertise in a well-defined medical device space with clear clinical need and commercial potential.

Highlights from their portfolio

• Pregnolia (Phase 2)
  Largest project at EUR 1.28M — the core product development and commercialization effort for their preterm birth diagnostic device.
• CervixCare
  Represents the validation and clinical translation phase, broadening from device development to integration into prenatal care protocols.